Ongoing PFS of >3 years in a patient with metastatic cholangiocarcinoma treated with durvalumab + chemotherapy
19 hours ago
byProf. Thomas Yau, Specialist in Medical Oncology, School of Clinical Medicine, The University of Hong Kong, Hong Kong; Dr. Jeffrey Wong, Fellow in Medical Oncology, Hong Kong
The patient was a female in
her early 50s, who presented was constitutional symptoms, including weight loss
and fatigue, in June 2022. Baseline FDG-PET scan discovered a 9 cm highly avid
liver mass, with multiple intrahepatic and lymph node metastases. The patient
was put on the TOPAZ-1 regimen (durvalumab 1,500 mg on day 1 plus gemcitabine
1,000 mg/m2 and cisplatin 25 mg/m2 on days 1
and 8 of a 21-day cycle for a total of 8 cycles followed by durvalumab
monotherapy Q4W thereafter). A follow-up FDG-PET after 8 cycles showed
quiescence across all lesions, indicating complete metabolic response. Last
seen in August 2025, the patient was alive and well, with an ongoing PFS of 39
months.
